<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction extraction-result-136 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extracted Data Details for extraction-result-136</h1>

        <div class="section">
            <h2>Extracted Data (Header)</h2>
            <div class="info-section">
                <p><strong>Extraction ID:</strong> extraction-result-136</p>
                <p><strong>Extraction Schema Used (ID):</strong> <a href="../schemas/extraction-schema-3.html">extraction-schema-3</a></p>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of the prevalence, types, and mechanisms of EGFR mutations in lung cancer across different populations, especially East Asians versus others, including proposed genetic, environmental, or lifestyle explanations for ethnic differences.</div>
                <p><strong>Paper ID:</strong> paper-70350334</p>
                <p><strong>Paper Title:</strong> Retrospect and Prospect for Lung Cancer in China: Clinical Advances of Immune Checkpoint Inhibitors</p>
                <p><strong>Paper Abstract:</strong> This review summarizes the developmental process of immunotherapy in lung cancer, ongoing international and domestic clinical trials in the field, and the challenges related to immunotherapy in the lung cancer patient population in China. The goal is to provide detailed information for future immunotherapy‐related clinical trials in China.</p>
                <p><strong>Cost:</strong> 0.01</p>
            </div>
        </div>

        <div class="section">
            <h2>Extracted Data (Details)</h2>
            <div class="extraction-instance-container" id="e136.0">
                <h3 class="extraction-instance">Extracted Data Instance 0 (e136.0)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of the prevalence, types, and mechanisms of EGFR mutations in lung cancer across different populations, especially East Asians versus others, including proposed genetic, environmental, or lifestyle explanations for ethnic differences.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>EGFR prevalence (China/East Asian)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Prevalence of epidermal growth factor receptor (EGFR) mutations in Chinese / East Asian non-small cell lung cancer (NSCLC) patients</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Reported frequencies of EGFR driver mutations in Chinese and East Asian NSCLC populations, with breakdowns by histology and clinically enriched subgroups; highlighted as substantially higher than in Western populations and as a defining molecular feature of Chinese NSCLC epidemiology.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Retrospect and Prospect for Lung Cancer in China: Clinical Advances of Immune Checkpoint Inhibitors</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>population_studied</strong></td>
                            <td>Chinese / East Asian NSCLC patients (general and histology- or clinic-enriched subgroups)</td>
                        </tr>
                        <tr>
                            <td><strong>sample_size</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>egfr_mutation_prevalence</strong></td>
                            <td>Reported values in the paper: ~28.4% in unselected Chinese NSCLC; 40.3%–64.5% in patients with adenocarcinoma; ~75% in certain clinically enriched populations (nonsmokers with adenocarcinoma); ~2.1%–8.0% in squamous cell carcinoma (SQCC). Elsewhere in the paper the prevalence in Chinese NSCLC is summarized as ~50% (statement reflecting aggregated estimates). (Units: %)</td>
                        </tr>
                        <tr>
                            <td><strong>mutation_types</strong></td>
                            <td>Paper reports 'sensitizing EGFR mutations' as a category (i.e., mutations that predict response to EGFR tyrosine kinase inhibitors) but does not provide exon-level breakdown (no specific exon 19 deletions, L858R, T790M frequencies, etc., are reported in this paper).</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_mechanisms</strong></td>
                            <td>The paper associates higher EGFR mutation prevalence with East Asian ethnicity, histology (adenocarcinoma), and clinical-enrichment (nonsmoker status). It lists genetic mutations as a risk factor generally but does not provide a detailed genetic-mechanistic explanation (no specific inherited variants, founder effects, or population-genetic mechanisms are proposed). Environmental/lifestyle factors (smoking, air pollution, indoor exposures) are listed as lung-cancer risk factors in the population but are not explicitly invoked as causal explanations for ethnic differences in EGFR mutation frequency.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_for_mechanisms</strong></td>
                            <td>Evidence presented is associative: epidemiologic summaries showing higher EGFR mutation frequencies in East Asian / Chinese cohorts and higher frequency in adenocarcinoma and nonsmokers (clinical enrichment); citation of population-level prevalence estimates. The paper also notes known risk-factor differences (smoking prevalence, exposures) in Chinese populations, and the clinical observation that EGFR/ALK alterations are more common in never-smokers.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_against_mechanisms</strong></td>
                            <td>The paper does not present direct evidence refuting genetic or environmental explanations; it explicitly states the reasons for differing PD-L1 expression and, by implication, for ethnic differences in molecular profiles remain unclear and calls for nationwide, multicenter studies. No concrete negative evidence (e.g., studies showing no ethnic genetic predisposition) is provided.</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_implications</strong></td>
                            <td>High EGFR mutation prevalence in Chinese/East Asian patients informs first-line therapy: EGFR TKIs (gefitinib, erlotinib, afatinib, icotinib) are recommended first-line for patients with sensitizing EGFR mutations. The paper also notes that EGFR-mutant (and ALK-rearranged) tumors are suggested to have lower objective response rates to PD-1/PD-L1 inhibitors, motivating trials to test combined or sequential TKI + immunotherapy strategies and the need for trials specifically targeting Chinese populations.</td>
                        </tr>
                        <tr>
                            <td><strong>study_design</strong></td>
                            <td>Narrative review / summary of epidemiology and clinical-trial data (literature review of published prevalence estimates and clinical observations).</td>
                        </tr>
                        <tr>
                            <td><strong>reference</strong></td>
                            <td>Lu S, Yu Y, Yang YI. Retrospect and Prospect for Lung Cancer in China: Clinical Advances of Immune Checkpoint Inhibitors. The Oncologist. 2019;24(Special Issue):S21-S30. doi:10.1634/theoncologist.2019-IO-S1-s02</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e136.1">
                <h3 class="extraction-instance">Extracted Data Instance 1 (e136.1)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of the prevalence, types, and mechanisms of EGFR mutations in lung cancer across different populations, especially East Asians versus others, including proposed genetic, environmental, or lifestyle explanations for ethnic differences.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>EGFR and immunotherapy response</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Association between EGFR mutations (and ALK rearrangements) and reduced responsiveness to PD-1/PD-L1 checkpoint inhibitors</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>The paper notes that tumors harboring EGFR mutations or ALK rearrangements—alterations more common in East Asian / Chinese patients and in never-smokers—have been suggested to show lower objective response rates (ORR) to PD-1/PD-L1 inhibitors, influencing trial design and treatment strategy.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Retrospect and Prospect for Lung Cancer in China: Clinical Advances of Immune Checkpoint Inhibitors</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>population_studied</strong></td>
                            <td>Reported in the context of East Asian / Chinese NSCLC patients and broader international trial observations (i.e., EGFR/ALK-positive subgroups across trials).</td>
                        </tr>
                        <tr>
                            <td><strong>sample_size</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>egfr_mutation_prevalence</strong></td>
                            <td>Not applicable to this specific entity beyond referencing that EGFR mutations are common (~28.4% unselected to ~50% aggregated in Chinese NSCLC as reported in the paper).</td>
                        </tr>
                        <tr>
                            <td><strong>mutation_types</strong></td>
                            <td>Referred to as 'EGFR mutations' broadly, including 'sensitizing' mutations that indicate EGFR TKI sensitivity; no exon-level specification in context of immunotherapy response.</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_mechanisms</strong></td>
                            <td>The paper suggests an epidemiologic/biologic correlation (EGFR/ALK alterations are more common in never-smokers and in East Asian patients) which may be associated with lower immunotherapy responsiveness—implicit mechanisms include lower tumor mutational burden in tumors driven by single oncogenic drivers and biologic differences in tumor-immune interactions, but the paper does not detail molecular mechanisms.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_for_mechanisms</strong></td>
                            <td>Cited clinical-trial observations and emerging literature: the paper states EGFR mutations and ALK rearrangements have 'been suggested' to be associated with lower ORR to PD-1 inhibitors and references ATLANTIC and other studies discussing outcomes in driver-positive patients; it uses these associations to justify trials combining TKIs and immunotherapies and trials designed for Chinese populations.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_against_mechanisms</strong></td>
                            <td>The paper does not present direct contradictory data; it notes that some heavily pretreated EGFR/ALK-positive patients may still derive benefit from PD-1/PD-L1 inhibitors in later lines (e.g., ATLANTIC trial data summarized), indicating the association is not absolute.</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_implications</strong></td>
                            <td>Because EGFR-mutant and ALK-rearranged patients may show lower ORR to checkpoint inhibitors, the paper recommends molecular testing and using EGFR TKIs as first-line therapy in EGFR-positive patients; it also calls for dedicated clinical trials (including combinations of TKIs and checkpoint inhibitors) to determine optimal treatment sequencing for these subgroups.</td>
                        </tr>
                        <tr>
                            <td><strong>study_design</strong></td>
                            <td>Narrative review referencing subgroup analyses from clinical trials and observational trial cohorts (review-level synthesis).</td>
                        </tr>
                        <tr>
                            <td><strong>reference</strong></td>
                            <td>Lu S, Yu Y, Yang YI. Retrospect and Prospect for Lung Cancer in China: Clinical Advances of Immune Checkpoint Inhibitors. The Oncologist. 2019;24(Special Issue):S21-S30. doi:10.1634/theoncologist.2019-IO-S1-s02</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>

        <div class="section">
            <h2>Potentially Relevant New Papers (mentioned by this paper)</h2>
            <ol>
                <li>Lung cancer molecular epidemiology in China: Recent trends <em>(Rating: 2)</em></li>
                <li>Epidemiology of lung cancer in China <em>(Rating: 2)</em></li>
                <li>PD-L1 expression and its relationship with oncogenic drivers in non-small cell lung cancer (NSCLC) <em>(Rating: 1)</em></li>
            </ol>
        </div>

        </div>

    </div>
</body>
</html>